Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ISRCTN17701271) titled '129Xenon MRI study of the effects of Mepolizumab on inflammation in the lungs of patients with chronic obstructive pulmonary disease (COPD)' on July 29.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Western University
Condition:
Chronic obstructive pulmonary disease (COPD)
Respiratory
Intervention:
All participants will receive mepolizumab 100mg delivered by auto-injector syringe subcutaneously once every 4 weeks from the end of visit 1 to week-48. Participants will come ...